Urbach Law advised Fairmed on a participation by Strides Pharma
Swiss based Fairmed Healthcare, a company with a portfolio of high-quality generic products, announced that it sold a majority stake to Strides Pharma Science Limited.
By Simon Urbach, Zurich
Sep 12 2019
<p><strong>Urbach Law advised Fairmed Healthcare Group with respect to a 70% participation of Strides Pharma Science Limited</strong></p><p>On September 12, 2019, <a>Fairmed Healthcare AG (Fairmed Healthcare)</a>, a Switzerland based company with a portfolio of high-quality generic products encompassing prescription and over-the-counter drugs across several therapeutic segments, announced that it sold a majority stake to <a>Strides Pharma Science Limited (Strides)</a>. The acquisition was made through subsidiary Strides Pharma Global Pte Ltd.</p><p>Strides Pharma Science Limited (Strides), is a global pharmaceutical company listed on the Bangalore Stock Exchange and National Stock Exchange of India, headquartered in Bangalore, India. Fairmed Healthcare announced that its market access in the DACH region and Strides vast international product portfolio is a highly complementary combination to pivot an extensive growth in the coming years.</p><p>Founded in Switzerland in 2012, Fairmed Healthcare aims to provide high-quality medicines at competitive prices. Fairmed Healthcare produces and markets a comprehensive range of generic prescription and OTC products for multiple indications. The headquarter is located in Zug with subsidiaries in Germany.</p><p>Urbach Law has advised Fairmed Healthcare Group in the transaction. The Urbach Law team was led by managing partner <a>Simon Urbach</a>.</p>